Manohar M, Goetz T E, Griffin R, Sullivan E
Department of Veterinary Biosciences, College of Veterinary Medicine, University of Ilhnois, Urbana 61801, USA.
Am J Vet Res. 1996 Sep;57(9):1354-8.
To determine the effects of phenylbutazone administration on heart rate and right atrial and pulmonary vascular pressures in Thoroughbreds during rest and during exercise performed at maximal heart rate.
7 healthy, exercise-conditioned Thoroughbreds.
Horses were studied on 3 occasions: without medication [control], after i.v. administration of phenylbutazone (4.4 mg/kg of body weight) at 12-hour intervals for 2 days and a final dose given 1 hour before exercise, and after i.v. administration of phenylbutazone for 2 days in the same manner, but with the final dose given 24 hours before exercise. Horses were studied at rest and during exercise performed at maximal heart rate on a treadmill. Right atrial and pulmonary vascular pressures were measured with catheter-tip manometers referenced at the point of the shoulder.
We did not detect significant differences in heart rate or right atrial and pulmonary vascular pressures among values recorded when horses were not given medication and values recorded when phenylbutazone was administered by either regimen. Exercise-induced pulmonary hemorrhage occurred in 6 of the 7 horses regardless of whether phenylbutazone was administered or the dosage regimen used.
In these Thoroughbreds, phenylbutazone treatment did not modify heart rate or right atrial and pulmonary vascular pressures at rest or during exercise capable of eliciting exercise-induced pulmonary hemorrhage. Thus, because phenylbutazone is a potent inhibitor of cyclooxygenase, prostaglandins probably do not play a role in mediating exercise-induced pulmonary hypertension in horses.
Phenylbutazone administration did not modify the pulmonary capillary hypertension in the strenuously exercising Thoroughbreds, and therefore, is unlikely to alter the prevalence or severity of exercise-induced pulmonary hemorrhage in Thoroughbred race-horses.
确定在纯种马休息时以及以最大心率进行运动期间,给予保泰松对心率、右心房压力和肺血管压力的影响。
7匹健康、经过运动训练的纯种马。
对马匹进行3次研究:未用药时[对照];以4.4毫克/千克体重的剂量静脉注射保泰松,每隔12小时注射1次,共注射2天,最后一剂在运动前1小时注射;以及以同样方式静脉注射保泰松2天,但最后一剂在运动前24小时注射。在跑步机上让马匹在休息时以及以最大心率进行运动期间接受研究。使用在肩部位置校准的导管顶端压力计测量右心房压力和肺血管压力。
我们未检测到在未用药时记录的值与采用任何一种给药方案注射保泰松时记录的值之间,心率、右心房压力和肺血管压力存在显著差异。无论是否给予保泰松或采用何种给药方案,7匹马中有6匹出现了运动诱发的肺出血。
在这些纯种马中,保泰松治疗并未改变休息时或能引发运动诱发肺出血的运动期间的心率、右心房压力和肺血管压力。因此,由于保泰松是一种强效环氧化酶抑制剂,前列腺素可能在介导马匹运动诱发的肺动脉高压中不起作用。
在剧烈运动的纯种马中,给予保泰松并未改变肺毛细血管高压,因此,不太可能改变纯种赛马运动诱发肺出血的发生率或严重程度。